Please select the eligibility criteria that correspond to the clinical trial below.
Title: The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology
Brief Summary: Over 50% of children dying from cancer still suffer from symptoms that could be effectively alleviated. The purpose of the Pediatric Quality of Life and Evaluation of Symptoms Technology (PediQUEST) Study was to evaluate whether providing feedback to families and providers about how the child is feeling improved child distress and quality of life (QoL) in children with advanced cancer.

PediQUEST is a computerized survey that asks the child and/or parents how the child has been feeling, i.e. whether the child had any physical or emotional symptoms, as well as how other aspects of life, such as school and friends, are going. After the survey is complete a report that summarizes patient/parent answers is printed. When a child reports moderate to high distress from any symptom an email is automatically sent to the primary providers (oncologist, nurse, and psycho-social clinician as well as the pain and palliative care services) alerting them about the child's distress.

In this study we evaluated whether using PediQUEST and providing printed reports to parents and providers reduced distress and improved quality of life in children with advanced cancer. In addition, we wanted to understand whether it was feasible to carry out a randomized controlled trial in children with advanced cancer. Finally, the data collected, will be used to describe the natural history of symptoms and quality of life as reported by the children.

Children enrolled in the study (or their parents) were asked to complete a PediQUEST survey at most once a week. A random half of the children received the feedback intervention, i.e. patients, parents, and providers received printed reports (and emails if the child was in distress). The other half only completed the PediQUEST surveys and did not receive reports. We analyzed data collected over 20 weeks of follow-up to see whether receiving PediQUEST reports had any effect on child distress and quality of life.


Options:
A: Inclusion Criteria:

* Sensorineural Hearing loss with pure-tone thresholds 25-70 dB HL at octave frequencies between 250 and 4000 Hz, 4 frequency PTA of ≥ 30 dB HL
* Non hearing aided wearer within the previous year
* Participants will be in good health (self-report)
* Normal or corrected to normal vision(≤20/50)

Exclusion Criteria:

* Conductive, or asymmetric hearing loss
* Hearing loss exceeding the limits that can be successfully aided with hearing aids (i.e., profound hearing loss)
* Hearing loss remediated with a cochlear implant (cannot wear hearing aids)
* Significant history of otologic or neurologic disorders
* Non English speaking participants
* Score of 23 or below on Mini-Mental Status Exam (MMSE)
* Score of 22 or below on Montreal Cognitive Assessment (MoCA)
* Any clinically significant unstable or progressive medical condition
* Any condition which, in the opinion of the investigator, places the participant at unacceptable risk if he or she were to participate in the study.
* Participants will be divided into low and high working groups based upon the results of their Lunner working memory reading span test. Once either high or low working memory group is filled (approximately 25 participants) we will selectively enroll participants to fill the other category.
B: Inclusion Criteria:

* Adult patients (aged 18 years or over) attending St James' University Hospital or the Christie Hospital Manchester who have been:
* Diagnosed with prostate cancer requiring radical radiotherapy treatment (including radiotherapy +/- brachytherapy boost) Or
* Diagnosed with anal, rectal, cervical, endometrial or vulval cancer requiring chemo-radiotherapy.
* Able and willing to give informed consent
* Able to read and understand English
* Access to the internet at home or on a smart device

Exclusion Criteria:

* Patients taking part in other clinical trials involving the completion of extensive patient reported outcome or quality of life measures
* Patients exhibiting overt psychopathology/cognitive dysfunction
C: Inclusion Criteria:

* Children \>=2-years old with at least a 2-week history of progressive, recurrent, or non-responsive cancer of any type or decision not to pursue cancer directed therapy.
* Child's parent must have spoken and written command of English or Spanish.
* Child's parent must have the ability to understand and complete self-administered surveys.

Exclusion Criteria:

* Patients who have an isolated relapsed solid tumor treated with surgery or radiation alone.
* Patients with hematological malignancies who have achieved remission after the first induction attempt, whose treatment plan includes their first Stem Cell Transplant (SCT), and have an identified donor (must meet all 3 criteria to be excluded).
* Patients who are not regular patients at one of the two participating institutions.
* Foster parents who do not have legal guardianship.
D: Inclusion Criteria:

* Women aged 18 and over
* With non-metastatic hormone receptor positive breast cancer
* Women will have to be at the end of primary treatment
* An indication for endocrine therapy treatment during 5 to 10 years
* be affiliated to a French social security scheme or beneficiary of such a scheme
* agreed to participate by signing a written consent

Exclusion Criteria:

* Participants who participate in another clinical trial where HRQoL is assessed
* Women for whom HRQoL evaluation is not possible (cognitive disorders, psychiatric disorders, people who do not speak French, etc.).
* Vulnerable participants (pregnant women, etc.)

Answer: C